CYTK · Cytokinetics Inc

NASDAQ Biotechnology Mid Cap Clavix B+
63.11+1.49  (+2.42%)

Price

Snapshot

50 fields · last close
Market Cap$8.57B
P/E—
Float132.0M
Beta0.41
Volatility10.3%
ExchangeNASDAQ
SectorBiotechnology
Cap tierMid cap
Macro sensitivityLow
Clavix score77.3
Price63.11
Change+2.42%
Prev Close61.62
Open62.32
Day Low61.50
Day High63.05
Avg Vol2
Avg $ Vol$145.3M
52W High88.31
52W Low54.30
52W Pos25.9%
From High−28.54%
From Low+16.22%
Max DD 1Y−29.96%
Spread0.10%
LiquidityNormal
SMA 20−3.12%
SMA 50−11.43%
SMA 200−10.00%
RSI (14)30.2
Vol 30D29.3%
Vol 90D35.9%
1Y Range54–88
Daily bars533
Perf Week+0.44%
Perf Month−14.95%
Perf Quarter−25.42%
Perf Half Y−7.13%
Perf Year+2.63%
Perf YTD+2.24%
Prev Day+2.42%
ClavixB+
Debt / Eq0.59
Curr Ratio4.53
Int Cover-10.7×
FCF Margin—
Rev Growth+376.6%
ProfitUnprofitable
LeverageLow
Sector rank9 / 35

Clavix risk grade

regraded every trading day
B+77.3/100

CYTK grades B+, 77.3 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (60, mixed). 4 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 9 of 35 in Biotechnology by Clavix score.

PriceMacroSectorNewsFinancial

How rough the ride is

CYTKBiotechnology median
Betavs the overall market · lower is steadier0.410.50
Volatilityannualized10.3%14.4%
Max drawdown, past yearworst peak-to-trough fall−30.0%—
Typical daily movemedian absolute daily change1.52%—
Days beyond ±3%of the last 252 sessions54 (21%)—

How its days are spread

Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.

52-week range

CYTK
61.62

The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.

Drawdown from the 1-year peak

CYTK

Percent below the running high over the last 12 months. Zero is a fresh high.

Market sensitivity

CYTKBiotechnology median
Beta to the markethow much it swings with the S&P 500 · lower is safer0.410.50
Macro sensitivityrate, dollar and credit exposure bucketLowLow 53% of 36

Where it sits on the macro scale

Low 19Moderate 9High 4Very High 4

Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.

Where it ranks in its sector

Sector
Biotechnology35 companies ranked
CYTK
#9 of 35

Rank by Clavix score within the sector. Right is the top of the sector.

Price performance

CYTK
1 week+0.4%
1 month−14.9%
Year to date+2.2%
1 year+2.6%

Context for the rank, not itself a risk measure.

No scored coverage for CYTK in the recent pool.

Balance sheet, against the sector

Debt / equityTotal debt vs shareholder equity · lower is stronger
0.59sector median 0.47 · 36 names
Current ratioShort-term assets vs liabilities · higher is stronger
4.53sector median 3.73 · 36 names
Interest coverageOperating income vs interest expense · higher is stronger
-10.7×sector median -0.2× · 32 names

The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.

Growth

CYTK
Revenue growthyear over year+376.6%

Financial Health is shown but does not count toward the grade. Why

0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.

Nearest peers by size

Biotechnology
TickerCompanyGradeMkt capP/EBeta
CAICaris Life Sciences IncC$8.35B79.370.40Compare
TGTXTG Therapeutics IncB-$8.32B19.161.82Compare
SYRESpyre Therapeutics Inc—$8.87B—2.95Compare
ARWRArrowhead Pharmaceuticals IncC+$8.21B—1.33Compare
PTGXProtagonist Therapeutics IncB$8.96B108.031.19Compare
KRYSKrystal Biotech IncB$9.51B39.710.64Compare
TWSTTwist Bioscience CorpD+$9.96B—2.15Compare
IONSIonis Pharmaceuticals IncB-$7.04B—0.38Compare

You just read one holding. Clavix reads the whole portfolio.

Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.